Evidence map›Paper›PMID 39624960›Full record

ArticleAnnals of medicine2024

Fragility in cardiovascular randomized controlled trials with primary continuous outcomes (2018-2022) from multi-perspectives assessment: a cross-sectional survey.

Xiaoqin Zhou, Weiqiang Ruan, Guiying Zhang, Huizhen Liu, Ting Wang, Jing Li, Liang Du, Jin Huang

Abstract read
In one paragraph

Article in Annals of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoqin ZhouDepartment of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, P.R. China.ORCID 0000-0003-4375-9159
Weiqiang RuanDepartment of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, P.R. China.
Guiying ZhangResearch Center of Clinical Epidemiology and Evidence-Based Medicine, West China Hospital, Sichuan University, Chengdu, P.R. China.
Huizhen LiuCenter of Biostatistics, Design, Measurement and Evaluation (CBDME), Department of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, P.R. China.
Ting WangCenter of Biostatistics, Design, Measurement and Evaluation (CBDME), Department of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, P.R. China.
Jing LiResearch Center of Clinical Epidemiology and Evidence-Based Medicine, West China Hospital, Sichuan University, Chengdu, P.R. China.
Liang DuResearch Center of Clinical Epidemiology and Evidence-Based Medicine, West China Hospital, Sichuan University, Chengdu, P.R. China.
Jin HuangDepartment of Urology, Innovation Institute for Integration of Medicine and Engineering, West China Hospital, Sichuan University, Chengdu, P.R. China.ORCID 0000-0001-7160-2314

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aims to assess the robustness of cardiovascular disease randomized controlled trials (RCTs) with primary continuous outcomes from a clinical perspective, utilizing the concepts of continuous fragility index (CFI), reverse continuous fragility index (RCFI) and their corresponding quotients (CFQ, RCFQ).

methodsA cross-sectional study was conducted, searching PubMed for cardiovascular RCTs published between January 1, 2018, to December 31, 2022, in eight high-impact journals. Inclusion criteria were phase III or IV trials with 1:1 randomization, reporting at least one primary continuous outcome. Data analysis involved altering each outcome until achieving the reversal of significance (ɑ = 0.05) to determine the CFI or RCFI. The fragility quotients were then calculated by dividing the CFI or RCFI by the sample size, and Spearman's correlation assessed correlation analyses.

resultsOf 3983 records were screened, and 64 RCTs (76 outcomes) were included. The fragility index was analysed with 72 outcomes. The overall median CFI was 7, with an associated median CFQ of 0.032. Nonsignificant

conclusionsThe findings suggest that changing only a small number of interventions (median of 7) could alter outcome significance. Reporting the fragility index alongside

Indexed as

Cardiovascular DiseasesRandomized Controlled Trials as TopicCross-Sectional StudiesHumansResearch DesignSample Sizecontinuous fragility indexFragility indexreverse fragility indexrobustness

Identifiers

PMID39624960
PMCPMC11616752

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.